ClinicalTrials.gg
RecruitingNCT06394869CREDIBLEUpdated Jul 2, 2026

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

An interventional study of Cxbladder Triage Plus in Hematuria - Cause Not Known, sponsored by Pacific Edge Limited. Recruiting at 20 sites in United States. Open to participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Pacific Edge Limited · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years to 88 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 361 studies in Carcinoma, Transitional Cell with a site in United States — 77 open to participants now, 141 under way, 14 of them phase 3. Carcinoma, Transitional Cell · United States.

Planned enrollment
6th of 333
1,000 · median 46
Started
2025
with 21 others
No phase
17 of 361
8 open now
Primary completion
2027-10
later than 82 of 140 live
Registered
311th of 361
by date

Among the 361 studies in Carcinoma, Transitional Cell with a site in United States, this one is the 6th largest by planned enrollment of the 333 interventional ones that give a count, is one of 22 that started in 2025, is one of 17 with no phase, reaches primary completion later than 82 of the 140 other live ones, and was the 311th registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

77 of the 361 studies in Carcinoma, Transitional Cell with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 88 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 361 studies in Carcinoma, Transitional Cell with a site in United States, or all of them as a file.
02

Study summary

This study includes adult patients who see a urologist because of blood in their urine. The amount is so small it can only be seen with a microscope. This is called microhematuria. There can be many reasons for microhematuria. One of them is bladder cancer. While bladder cancer is one of the biggest worries, it is only found in few of these patients.

Most microhematuria patients will have a cystoscopy to look inside the bladder. During a cystoscopy, a small camera is inserted into the bladder. This is done through the urethra, the tube that passes urine from the bladder to the outside. In some patients it can cause pain or anxiety. Not all patients have a cystoscopy. Those that don't, usually return for a urine sample within 6 months. This is done to check if there is still blood in their urine.

This study is conducted to find out if the use of "Cxbladder Triage Plus" changes the number of cystoscopies in microhematuria patients. Cxbladder Triage Plus is also called "Triage Plus". It is a lab test that was developed to check how likely urothelial carcinoma is present in the bladder. Urothelial carcinoma is by far the most common type of bladder cancer. For the test, the patient voids some urine into a cup. A laboratory then checks the urine of specific genetic material. Abnormalities can be a sign of urothelial carcinoma. The result indicates if the urine is more like most normal urine or more like that of urothelial carcinoma patients.

The study is done to find out how Triage Plus changes the number of cystoscopies. Study participants first void urine into a cup. The urine is used for the Triage Plus test. The patients are then assigned to one of two groups. The assignment is random. This means the nobody can influence the assignment. The chance to be assigned to either group is the same. In the test group, the urologist will receive the Triage Plus result and discuss it with the patient. Together they decide whether to do a cystoscopy. In the control group, the urologist will not receive the Triage Plus result. The patient will also not get the result. The urologist and patient will follow standard of care to decide whether to do a cystoscopy.

For test group patients, the study gives a recommendation whether to proceed with cystoscopy. It is based on the patient's Triage Plus result. The urologist and patient do not need to follow the recommendation. If the urologist does not follow it, they will complete a survey. The survey has only one question. It is asking for the reasons of the decision.

After making their decision, patients will follow the chosen pathway. Data on the performed procedures are collected. The diagnosis will also be documented. Data will be collected for up to about 9 months.

To see how Triage Plus changes the number of cystoscopies, these will be counted in each group and then compared.

03

Conditions studied

  • Hematuria - Cause Not Known

Keywords

  • microscopic hematuria
  • microhematuria
  • urothelial carcinoma
  • bladder cancer
04

Who can participate

Ages eligible
18 Years to 88 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is referred for assessment of recent hematuria, defined as either:

    1. Microscopic hematuria (≥3 RBC/HPF or equivalent) on urine microscopy obtained within 180 days prior to enrollment, OR
    2. Hematuria detected by dipstick analysis (≥2+ blood or equivalent) at referral and confirmed on the same calendar day and prior to enrollment, with urine microscopy collected on the same day as enrollment
  2. Physically able to provide a voided urine sample from a bladder that has not been surgically altered.
  3. Able to give informed, written consent.
  4. Able and willing to comply with study requirements.
  5. Must be 19 or the legal age of consent in the jurisdiction in which the study is taking place to 88 years of age inclusive, at the time of signing the .
  6. Ability to comprehend written and spoken English sufficiently to independently follow all study procedures. Or ability to comprehend Spanish with access to an English-Spanish interpreter for all study related verbal instructions and discussions.

Exclusion criteria

Exclusion Criteria:

  1. Prior history of bladder .
  2. Prior history of upper tract UC or prostatic urethral UC.
  3. History of gross hematuria requiring instrumentation or hospitalization within the last 12 months
  4. Reconstructed or diverted bladder (e.g., bladder augmentation, ileal conduit, Indiana pouch)
  5. Indication to recommend cystoscopy other than MH (e.g., bothersome benign prostatic hyperplasia symptoms and desires a procedure, weak stream with concerns for urethral stricture).
  6. Cystoscopy due to another condition or anatomy.
  7. History of pelvic radiation.
  8. Currently receiving systemic chemotherapy or has had systemic chemotherapy within the last 6 weeks.
  9. History of schistosomiasis.
  10. History of chronic (>3 months) indwelling Foley catheter or chronic (>3 months) bladder stones.
  11. Known current pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Test Arm

    The site will receive the Cxbladder Triage+ result and the urologist study investigator discuss it with the patient before making a shared decision whether or not to proceed with cystoscopy.

    Diagnostic Test: Cxbladder Triage Plus

  • No intervention
    Control arm

    Neither the site nor the patient will receive the Cxbladder Triage+ result. The decision whether or not to proceed with cystoscopy will be made following standard of care.

Interventions

  • Diagnostic testCxbladder Triage Plus

    Cxbladder Triage Plus is a lab developed, test that is using RNA and DNA biomarkers in the urine to assess the likelihood of the presence of urothelial carcinoma in the bladder.

06

What researchers measure

Primary outcomes

  1. Cystoscopy rate

    Difference in the proportion of cystoscopies performed in each arm.

    Time frame: 3 months from the decision to perform or not perform cystoscopy.

Secondary outcomes

  1. Detection of urothelial carcinoma (UC)

    Difference in the proportion of UCs found in each arm.

    Time frame: At the end of the current investigation, i.e. when a diagnosis was made or it was decided not to perform diagnostic procedures other than surveillance. Expected within approximately 120 days after sampling.

  2. Cxbladder Triage Plus performance and test negative rate.

    Number of false positive, true positive, false negative and true negative test results when comparing the Triage Plus result to the results of histopathologically confirmed cystoscopy.

    Time frame: Up to 180 days after the investigational decision (whether to proceed with cystoscopy) was made.

  3. Persistent hematuria.

    Rate of persistent hematuria in patients choosing surveillance.

    Time frame: At urinalysis 90-180 days (of the decision to proceed with surveillance)

  4. Missed UCs

    Number of UCs in both arms identified during the surveillance phase.

    Time frame: At the end of the current investigation, i.e. when a diagnosis was made or it was decided not to perform diagnostic procedures other than surveillance. Expected within approximately 120 days after sampling.]

  5. Imaging Rates

    Change in imaging rates between arms

    Time frame: 3-months prior to 6-months post enrollment

  6. Rate of imaging procedures

    Sub-analyses on AUA risk categories for primary and secondary objectives

    Time frame: 3 months from the decision to perform or not perform cystoscopy.

Other outcomes

  1. Physician rationale

    Physician-reported reasons for not following the study recommended pathway based on the Detect+ result.

    Time frame: After reviewing the Detect+ result and giving their recommendation, before cystoscopy (if applicable). Expected once and within 90 days of sampling

  2. Imaging Utilisation

    Change in number and modality of imaging procedures

    Time frame: From 3 months prior to 6 months post enrollment.

  3. Dipstick Subgroup

    Proportion of subjects enrolled via dipstick-positive hematuria who meet guideline-defined microhematuria based on urine microscopy.

    Time frame: At enrolment

07

Study locations

17 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Oct 2027, 30 months after the start.

Of 29 interventional studies with no phase under Carcinoma, Transitional Cell, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 23. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2024
First posted
May 1, 2024
StartActual
Apr 29, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Apr 2028
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06394869
Lead sponsor
Pacific Edge Limited
Responsible party
Sponsor
First posted
May 1, 2024
Start date
Apr 29, 2025
Primary completion
Oct 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Jul 2, 2026

Study contacts

Donna Smith
Contact
Donna.Smith@pacificedgedx.com
+64212436696
Tony Lough, PhD
Contact
tony.lough@pelnz.com
+64 (0)21 0223 8591
Tony Lough, PhD
study chair · Pacific Edge Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion